Stock Analysis

Akeso Full Year 2022 Earnings: Misses Expectations

Source: Shutterstock

Akeso (HKG:9926) Full Year 2022 Results

Key Financial Results

  • Revenue: CN¥837.7m (up 271% from FY 2021).
  • Net loss: CN¥1.17b (loss widened by 8.7% from FY 2021).
  • CN¥1.42 loss per share (further deteriorated from CN¥1.32 loss in FY 2021).
SEHK:9926 Earnings and Revenue Growth March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Akeso Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 4.8%.

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 17% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Akeso.

Valuation is complex, but we're helping make it simple.

Find out whether Akeso is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis